Protocol · graded by use, three uses
Alcohol reduction
Blood pressure in people drinking more than two drinks a day.
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Corrected.
The record said no randomized trial had assigned people to drink less and measured mortality. Re-running its stored search found Kristenson et al. (Alcohol Clin Exp Res, 1983; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 6135365): 585 middle-aged Malmo men with heavy drinking randomized to counseling to cut down or a letter, with mortality about half as high over 6 years in the intervention group (60-month report, Kristenson et al., Alcohol, 1985; PMID 2862882). A single unreplicated trial on a hard endpoint An outcome that matters directly to a person and is counted without judgment, such as death, heart attack, stroke or fracture. is C, now its own row. The headline stays B on blood pressure, and the record's endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. field, which still named mortality, now names blood pressure. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 2862882 PMID 6135365
The headline was held at D Route 1 because the record was framed on mortality, which no trial has tested, while its uses carried B (blood pressure above two drinks a day; Xin et al., Hypertension, 2001; PMID 11711507; Roerecke et al., Lancet Public Health, 2017; PMID 29253389) and C (AF recurrence; Voskoboinik et al., N Engl J Med, 2020; PMID 31893513). The site's headline letter is the best graded use on every other record, and a D on the index beside a B inside the record read as 'tested or untested' for a thing with replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. randomized evidence. The headline now follows the best use; the absence of mortality trials is stated in the reading and carries no letter. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 11711507 PMID 29253389 PMID 31893513
The record leaned on an observational Research that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other. global analysis and said only that no randomized trial exists. The randomized evidence it was missing is now cited: Xin 2001 (PMID 11711507) and Roerecke 2017 (PMID 29253389) pooled 15 and 36 trials and found blood pressure falls with reduced drinking, but only in people drinking more than two drinks a day; that is a new use at B. Voskoboinik 2020 (PMID 31893513), abstinence and AF recurrence, is a new use at C. Gardiner 2025 (PMID 39631226) is described as what it is, acute alcohol-before-sleep studies showing REM disruption, not a trial of reducing intake. The GBD 'zero is safest' conclusion is kept as context only. Headline D Route 1 held pending editor confirmation.PMID 11711507 PMID 29253389 PMID 31893513 PMID 39631226
Every change to a letter on this site is dated and published. The full evidence log →
This page is about drinking less alcohol. Pooled studies found that cutting back lowered blood pressure in people who drank more than two drinks a day. The biggest drop, about 5 points in the top number, came in heavy drinkers who cut their intake in half. There was no clear change in people who drank two or fewer. One study found fewer repeat bouts of an irregular heartbeat when regular drinkers stopped. One old study of Swedish men found fewer deaths, but it was never repeated.
The B belongs to one of the three uses graded on this record. The other two carry their own letters.
This record carries a separate letter for each thing it has been measured on. The headline grade is the best of them, and it does not transfer to the others.
Two pooled analyses of randomized trials agree: Xin et al. (2001; PMID 11711507), 15 trials, systolic pressure down 3.3 mmHg; Roerecke et al. (2017; PMID 29253389), 36 trials, the effect present only above two drinks a day and largest (5.5 mmHg systolic) in people drinking six or more who halved their intake. Replicated randomized evidence on a surrogate: B. No effect was found at two or fewer drinks a day.
One open-label Everyone in the trial knows which treatment they are receiving, so expectations can shape the results, especially for symptoms people report themselves. randomized trial, Voskoboinik et al. (N Engl J Med, 2020; PMID 31893513), 140 patients: abstinence cut recurrence from 73 to 53 percent (hazard ratio How often an event happened in the treated group compared with the control group over the same period. A ratio of 0.80 means 20 percent fewer events. 0.55, 95% CI 0.36 to 0.84) and AF burden from 1.2 to 0.5 percent of time over 6 months. A clinical endpoint, but a single trial, open-label, 6 months: C.
Kristenson et al. (Alcohol Clin Exp Res, 1983; PMID 6135365): 585 middle-aged Malmo men with raised GGT randomized to repeated counseling to cut down, with GGT as feedback, or a letter; sick days, hospital days and mortality over 6 years were lower in the intervention group, mortality by about half. Kristenson et al. (Alcohol, 1985; PMID 2862882) reports the same trial at 60 months. One trial from one city in the 1970s, mortality not its prespecified primary outcome, the number of deaths not stated in the abstract, and never repeated: C.
Pooled randomized trials show that drinking less lowers blood pressure in people drinking more than two drinks a day, and one trial shows fewer atrial fibrillation recurrences in regular drinkers with AF. No randomized trial has assigned people to drink less and measured death or major cardiovascular events; the global observational analysis concluding that zero is the level that minimizes health loss is context, not grade evidence.
Why this gradeThe reasoning, and what the grade does not cover.
Grade B, the record's best use: blood pressure in people drinking more than two drinks a day, from pooled randomized trials. Xin et al. (Hypertension, 2001; PMID 11711507) pooled 15 trials, 2,234 participants, systolic 3.3 and diastolic 2.0 mmHg lower; Roerecke et al. (Lancet Public Health, 2017; PMID 29253389) pooled 36 trials, 2,865 participants, and found the fall confined to people drinking more than two drinks a day. Blood pressure is a surrogate, which caps the letter at B. Atrial fibrillation recurrence in regular drinkers is C on one open-label trial (Voskoboinik et al., N Engl J Med, 2020; PMID 31893513). The headline moved from D Route 1 in October 2026 to follow the best use, as every other graded record's headline does.
WHAT THIS GRADE DOES NOT COVERmajor cardiovascular events, where no randomized trial has assigned people to drink less; mortality, which rests on one trial of counseling heavy drinkers in Malmo in the 1970s (Kristenson et al., 1983; PMID 6135365) and is graded C on its own row; the observational conclusion that zero drinking minimizes health loss (GBD 2016 Alcohol Collaborators; PMID 30146330), which carries no letter; and people drinking two drinks a day or fewer, in whom the pooled trials found no significant blood pressure change.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
The evidence, in fullSeven papers, each linked to its PubMed record.
Headline B on the best use, blood pressure in heavier drinkers. Mortality and major cardiovascular events carry no letter: no randomized trial has assigned people to reduced drinking and measured those outcomes. The GBD 2016 Alcohol Collaborators (Griswold et al., Lancet, 2018; PMID 30146330) concluded from observational data across 195 countries that the level of consumption minimizing health loss is zero; that conclusion is observational and disputed, and no letter here rests on it. Randomized evidence on other endpoints: Xin et al. (Hypertension, 2001; PMID 11711507) pooled 15 randomized trials, 2,234 participants, and found alcohol reduction lowered systolic pressure 3.3 mmHg and diastolic 2.0 mmHg; Roerecke et al. (Lancet Public Health, 2017; PMID 29253389) pooled 36 trials, 2,865 participants, and found the fall confined to people drinking more than two drinks a day, with no significant change at two or fewer. Voskoboinik et al. (N Engl J Med, 2020; PMID 31893513) randomized 140 regular drinkers with atrial fibrillation to abstinence or usual drinking; recurrence fell (53 versus 73 percent, hazard ratio 0.55) and AF burden fell. Gardiner et al. (Sleep Med Rev, 2025; PMID 39631226) pooled 27 experimental studies in which alcohol was given before sleep: REM sleep was delayed and shortened even at about two drinks, while total sleep time and efficiency were uncertain; these are acute alcohol-administration studies, not trials of reducing intake.
Weekly alcohol units using a standardized diary at baseline and monthly. The 14 units/week (UK) and 7 drinks/week (NIAAA lower-risk) figures are published guideline thresholds, not trial-derived treatment goals. Liver enzymes (ALT, AST, GGT) and MCV at baseline and 3 months if prior intake was heavy. Validated screening tools (AUDIT-C) to track intake change over time.
Evidence notes: randomized trial, meta-analysis A study that pools the numbers from several trials into one combined estimate., observational
Endpoint graded: Blood pressure in people drinking more than two drinks a day (surrogate)
Last reviewed: July 2026
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
As studiedDose, form, population and duration for every use.
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(alcohol[tiab] AND (reduction[tiab] OR abstinence[tiab] OR abstain*[tiab])) AND (blood pressure[tiab] OR atrial fibrillation[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) AND humans[mesh]Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →